Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme.

Besiroglu, MehmetShbair, Abdallah TmYasin, Ayse IremTopcu, AtakanTurk, HACI MEHMETDemir, Tarik2021-02-092021-02-092021-01-01Besiroglu M., Shbair A. T. , Yasin A. I. , Topcu A., Turk H. M. , Demir T., -Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme.-, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, cilt.31, ss.39-44, 2021http://hdl.handle.net/20.500.12645/28373Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme.Article8510031189310.29271/jcpsp.2021.01.3933546531